ZTX
LIVE

Serial Number

79299712

Owner

Bioreperia AB

Attorney

Arlene D. Hanks

Filing Date

Jun 15, 2020

Add to watchlist:

No watchlists yet
View on USPTO

ZTX Trademark

Serial Number: 79299712 • Registration: 6841276

ZTX is a trademark filed by Bioreperia AB on June 15, 2020. The trademark is classified under Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Bioreperia AB (2 trademarks)

Westmansgatan 47 3 tr

Entity Type: 64

Trademark Details

Filing Date

June 15, 2020

Registration Date

September 13, 2022

Published for Opposition

August 3, 2021

Goods & Services

Database management for others, namely, input, processing, checking, storage and retrieval of computer data; data processing services in the nature of processing and control of computerized information; data, database, file and records management in relation to business management and administration; retail store services featuring image apparatus, computers, computer programs, pharmaceutical preparations, pharmaceutical goods and goods for medical diagnostics; compiling indexes of information for others relating to information, homepages and other resources available via global computer networks and other electronic communications networks; compilation of statistical data relating to medical research for business purposes

Medical services; analysis and examination of medical images for purposes of medical diagnosis and providing medical advice relating to pharmacology; online analysis and examination of medical images for purposes of medical diagnosis and providing medical advice relating to pharmacology; medical laboratory analysis services relating to the medical treatment of persons; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; consultancy services relating to health care; conducting of medical studies for medical diagnostic or treatment purposes in the field of oncology; medical services provided by analysis and examination of medical files, data, documents, text, videos, sound and images; medical services provided online by analysis and examination of medical files, data, documents, text, videos, sound and images; providing medical information

Diagnostic, examination, and monitoring equipment, namely, medical diagnostic apparatus for testing cancer tissues incorporating recorded operating system software; medical imaging apparatus; image management systems for medical purposes, namely, medical imaging apparatus with embedded operating system and analytical software

Scientific and technological services, namely, research and product design in the fields of medicine and pharmacology; industrial analysis services, namely, laboratory analysis services in the medical and pharmaceutical fields; industrial research in the field of medicine and pharmacology; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; drug discovery services; providing information and data relating to pharmaceutical and medical research and development; software design and development; software as a service (SaaS) services featuring software for recording, transmission, reproduction, storage and processing of files, test results, documents, texts, videos and images in the pharmaceutical and medical fields; platform as a service (PaaS) featuring computer software platforms for processing of pharmaceutical and medical files, test results, documents, texts, sound and images; computer services, namely, cloud hosting provider services; programming of computer software for pharmaceutical and medical application for others; electronic data storage; electronic storage of electronic media, namely files, data, documents, text, videos and images; computer services, namely, electronic digitizing of photographic images for medical purposes

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 3, 2023 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Dec 14, 2022 FICS
FINAL DISPOSITION PROCESSED
Dec 13, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 13, 2022 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 13, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 13, 2022 R.PR
TTAB RELEASE CASE TO TRADEMARKS
Aug 5, 2022 TMBN
OPPOSITION TERMINATED NO. 999999
Aug 5, 2022 OP.T
OPPOSITION DISMISSED NO. 999999
Aug 5, 2022 OP.D
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
May 30, 2022 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
May 11, 2022 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
May 11, 2022 OPNR
REFUSAL PROCESSED BY IB
Feb 28, 2022 RFNP
OPPOSITION INSTITUTED NO. 999999
Feb 2, 2022 OP.I
OPPOSITION NOTICE (IB REFUSAL) SENT TO IB
Feb 1, 2022 OPNS
OPPOSITION NOTICE (IB REFUSAL) CREATED
Feb 1, 2022 OPNC
EXTENSION OF TIME TO OPPOSE RECEIVED
Sep 2, 2021 ETOF
NOTIFICATION PROCESSED BY IB
Aug 15, 2021 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 3, 2021 NPUB
PUBLISHED FOR OPPOSITION
Aug 3, 2021 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jul 28, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jul 28, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 14, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 24, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 24, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 24, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 24, 2021 TROA
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
Jun 16, 2021 LIME
LIMITATION OF GOODS RECEIVED FROM IB
Jun 12, 2021 LIMG
REFUSAL PROCESSED BY IB
Jan 24, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 30, 2020 RFCS
REFUSAL PROCESSED BY MPU
Dec 29, 2020 RFRR
APPLICATION FILING RECEIPT MAILED
Dec 18, 2020 MAFR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 15, 2020 RFCR
NON-FINAL ACTION WRITTEN
Dec 14, 2020 CNRT
ASSIGNED TO EXAMINER
Dec 14, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 14, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 10, 2020 REPR